LitAlert ~~ GeneLit.com

    • Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study.
    • Uson PLS Jr, Kunze KL, Golafshar MA, Botrus G, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Kahn A, Klint M, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T, Samadder NJ.
    • Dig Dis Sci. 2022 Feb 5. doi: 10.1007/s10620-022-07387-x. Epub ahead of print.
    • “It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing.
    • Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM.
    • Hered Cancer Clin Pract. 2022 Feb 5;20:6. doi: 10.1186/s13053-022-00212-6.
    • Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
    • Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara Jr PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, on behalf of theGALAHAD investigators.
    • Lancet Oncol. 2022 Feb 4:S1470-2045(21)00757-9. doi: 10.1016/S1470-2045(21)00757-9. Epub ahead of print.